Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study.
Latest Information Update: 15 Oct 2024
Price :
$35 *
At a glance
- Drugs Ravulizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Acronyms PNH-RECORD
- Sponsors AstraZeneca
- 15 Oct 2024 New trial record